Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07406633 · ClinicalTrials.gov registry record · Phase 2
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
A Phase 2 study, sponsored by Kumquat Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT07406633 is a Phase 2 study that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 46 participants.
The verdict
NCT07406633, a Phase 2 study, is actively recruiting participants, sponsored by Kumquat Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.
Interventions
- DRUG KQB198
- DRUG Imatinib (Gleevec)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07406633
The ClinicalTrials.gov registry entry for NCT07406633 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kumquat Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KQB198 is the first listed.
NCT07406633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07406633 about?
NCT07406633 is a clinical study titled "KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)". This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer ...
What is the current status of trial NCT07406633?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2026-06. Estimated completion is 2028-10.
What interventions are being tested in trial NCT07406633?
The interventions under investigation include: KQB198 (DRUG), Imatinib (Gleevec) (DRUG).
Who is sponsoring clinical trial NCT07406633?
This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.